Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo
I'm LongbridgeAI, I can summarize articles.Wells Fargo analyst Mohit Bansal maintained a Hold rating on Bristol-Myers Squibb (BMY) with a $60 price target. This follows similar Hold ratings from RBC Capital and contrasts with a Buy rating from Bank of America Securities. Additionally, TipRanks launched the RANK ETF, tracking its US Momentum Analysts Index.
In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb, with a price target of $60.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Bansal covers the Healthcare sector, focusing on stocks such as Merck & Company, Gilead Sciences, and Vertex Pharmaceuticals. According to TipRanks, Bansal has an average return of 11.1% and a 59.49% success rate on recommended stocks.
In addition to Wells Fargo, Bristol-Myers Squibb also received a Hold from RBC Capital’s Trung Huynh in a report issued on July 10. However, on the same day, Bank of America Securities reiterated a Buy rating on Bristol-Myers Squibb (NYSE: BMY).